A single infusion of an experimental gene‑editing drug slashed LDL cholesterol by as much as 62 percent in a 35‑patient interim trial. The study, published in the New England Journal of Medicine, signals a possible one‑off cure for heart disease—a disease that claims nearly 800,000 U.S. lives a year.

The trial, led by Dr. Sekar Kathiresan of Verve Therapeutics—now a unit of Eli Lilly—uses a fat‑coated CRISPR particle to disable the PCSK9 gene in liver cells. By erasing a single DNA letter, the therapy boosts the liver’s clearance of LDL, lowering blood levels without daily pills.

Although the interim data are promising, the study will expand to 85 participants and later to 200, with regulators demanding 15‑year safety follow‑up. Critics caution that, until larger trials confirm durability, the therapy remains experimental and its price—potentially far below the multi‑million dollar tag of rare‑disease gene treatments—remains uncertain.

For patients who struggle with daily statins or pricey PCSK9 inhibitors, a one‑time infusion could transform adherence and reduce cardiovascular events. Stakeholders now focus on scaling manufacturing, securing reimbursement, and navigating regulatory pathways that could make a single‑infusion cure a reality for millions.